Skip to main content

Table 1 Initial characteristics of the disease during hospitalisation of patients assessed at M6 and M12 (n = 120)

From: Fatigue and quality-of-life in the year following SARS-Cov2 infection

Variables Number (%) Median [IQR]
Socio-demographic characteristics   
 Age   63.50 [54.00–71.25]
  > 70 years old 32 (26.67)  
 Men 65 (54.17)  
 Live at home 120 (100.00)  
Symptoms   
 Fever 92 (76.67)  
 Cough 88 (73.33)  
 Dyspnoea 80 (66.67)  
 Headache 19 (15.83)  
 Diarrhoea 46 (38.30)  
 Anorexia 20 (16.67)  
 Ageusia 12 (10.00)  
 Anosmia 17 (14.17)  
 Muscle pains 34 (28.33)  
 Abdominal pains 9 (7.50)  
Clinical situation   
 Severe clinical profilea 42 (35.00)  
 Heart rate (beat/min)   89.00 [80.00–99.75]
  > 45 and ≤ 120 112 (94.92)  
  > 120 6 (5.08)  
 Respiratory rate (/min)   21.50 [18.00–28.00]
  > 30 20 (17.86)  
 Systolic blood pressure (mmHg)   130.00 [120.0–143.5]
  > 140 33 (28.45)  
 Glasgow score   15.00 [15.00–15.00]
  < 15 5 (4.67)  
 Early Warning Score   6.00 [3.00–9.00]
  ≤ 4 44 (39.64)  
  > 4 and ≤ 6 18 (16.22)  
  > 6 49 (44.14)  
Biology   
 Creatinine (µmol/L)   78.00 [61.50–94.50]
  > 120 20 (16.81)  
 CRP (mg/L)   92.00 [34.38–157.25]
  < 40 33 (28.45)  
  ≥ 40 and < 150 52 (44.83)  
  ≥ 150 31 (26.72)  
 Lymphocytes (G/L)   0.90 [0.60–1.20]
  < 1.5 100 (84.03)  
 Neutrophils (G/L)   5.10 [3.30–6.70]
  < 2 4 (3.39)  
 Bacterial co-infection 4 (3.33)  
Therapeutics   
 Antiviralsb 107 (89.17)  
 Hydroxychloroquine 26 (24.30)  
 Antibiotic therapy 115 (95.83)  
 Corticoids 80 (66.67)  
 Anticoagulants 111 (92.50)  
Evolution   
 Transfer in ICU 35 (29.17)  
 Oxygen therapy 52 (43.33)  
 Pulmonary embolism 9 (7.50)  
 Home visits 88 (73.33)  
 Follow-up care and rehabilitation 31 (26.67)  
 Re-hospitalisation 5 (4.17)  
  1. aIncludes severe initial pneumonia and acute respiratory distress syndrome (ARDS). Criteria for severe pneumonia were: fever and SpO2 < 90% or respiratory rate > 30/min or acute respiratory failure needing respiratory support (invasive or not) and/or admission in ICU and/or acute circulatory failure (sepsis or septic shock)
  2. bIncludes: Lopinavir/Ritonavir or Darunavir/Ritonavir or Remdesivir